Case Western Reserve Researchers Receive Major NIH Renewal Grant to Build on Progress in Understanding Crohn's Disease

Fabio Cominelli, MD, PhD, a professor in the departments of Medicine and Pathology at Case Western Reserve University School of Medicine and Director of Case’s Digestive Health Research Institute, has received a five-year renewal program project grant totaling $9.7 million from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institute of Health, with the goal of better understanding the origins of Crohn's disease and eventually developing a cure.

Among the objectives is to discover why mice in which gut inflammation spontaneously occurs, appear to have an innate immunity defect that predispose them to develop experimental Crohn’s disease.

The aim is to replicate these findings in humans, leading to a cure for at least some patients with this devastating ailment. Symptoms of Crohn’s disease include severe abdominal pain and cramps, weight loss, recurrent diarrhea, loss of appetite, and fatigue. About 780,000 Americans have Crohn's disease.

The exact cause(s) of the disorder are unknown, making a cure elusive. In the past, diet and excess stress were leading candidates, but today’s consensus is that while these may make Crohn's disease worse, they don't precipitate it. Instead, a combination of genetics and a faulty immune system probably are involved. Specifically, growing evidence, including pioneering work done by Cominelli and his colleagues, suggests that Crohn's disease may be caused by a poorly regulated innate immune response against unknown antigens in a genetically-susceptible person. (Antigens are foreign substances in the body that produce an immune response).

Before and during the first five-year project, my colleagues and I provided evidence of the importance of innate immunity and the role of what’s called the NOD2 gene,” said Cominelli. “This gene supplies instructions for making a protein that helps protect the body against foreign invaders in a disease called ileitis.” Ileitis is an inflammation of the lower part of the small intestine, known as the ileum. Crohn’s disease is inflammation of both the small and large intestines. Understanding how the body may guard itself against ileitis is an important step in understanding how it may guard itself against Crohn’s disease.

The Cominelli team found that a deficit in the body’s natural immune system may play an important role in causing the disease. The immune system includes numerous infection-fighting cells including those regulated by the NOD2 gene. In studying ileitis in mice, Cominelli and his colleagues found a shortage of these cells and, as a result, harmful antigens weren’t being removed from the body. Based on this finding, a cure for Crohn’s disease could include developing an alternative source of these cells to boost the body’s immune system.

The overall renewal project, which is multidisciplinary in nature, will continue to be directed by Cominelli. It comprises three component projects: he will head the first; Derek Abbott, MD, PhD, associate professor of pathology and medicine, will direct the second; and Theresa Pizarro, PhD, professor of pathology and medicine, will lead the third. They will be supported by a team of colleagues, including Alex Rodriguez-Palacios PhD, DVM, assistant professor of medicine, providing core, essential assistance.

All three specific projects will expand the study of molecules such as the NOD2 gene, as well as the closely related NOD1, IL-1, and IL-33 genes, and their relationship with the gut microbiome (the bacteria that populate our intestines). IL-1 and IL-33, or Interleukin-1 and -33, are proteins that promotes the production of immune cells to fight infections.

“We are extremely grateful to the National Institute of Diabetes and Digestive and Kidney Diseases for their continued confidence in us,” said Cominelli. “My colleagues and I are committed to translating our research into new medications and treatments that will rectify the gaps in the immune systems of patients with Crohn’s disease, ultimately resulting in a cure.”


Research reported in this publication was supported by the National Institute Of Diabetes And Digestive And Kidney Diseases of the National Institutes of Health under Award Number P30DK097948. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

For more information about Case Western Reserve University School of Medicine, please visit the School of Medicine's website.

Founded in 1843, Case Western Reserve University School of Medicine is the largest medical research institution in Ohio and is among the nation's top medical schools for research funding from the National Institutes of Health. The School of Medicine is recognized throughout the international medical community for outstanding achievements in teaching. The School's innovative and pioneering Western Reserve2 curriculum interweaves four themes--research and scholarship, clinical mastery, leadership, and civic professionalism--to prepare students for the practice of evidence-based medicine in the rapidly changing health care environment of the 21st century. Nine Nobel Laureates have been affiliated with the School of Medicine.

Annually, the School of Medicine trains more than 800 MD and MD/PhD students and ranks in the top 25 among U.S. research-oriented medical schools as designated by U.S. News & World Report's "Guide to Graduate Education."

The School of Medicine is affiliated with University Hospitals Cleveland Medical Center, MetroHealth Medical Center, the Louis Stokes Cleveland Department of Veterans Affairs Medical Center, and the Cleveland Clinic, with which it established the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University in 2002.

Media Contact(s):

Marc Kaplan
Associate Dean, Marketing and Communications
The School of Medicine
Case Western Reserve University
Office: 216-368-4692